Cargando…
Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases
Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease which affects ≈25% of the adult population worldwide, placing a tremendous burden on human health. The disease spectrum ranges from simple steatosis to steatohepatitis, fibrosis, and ultimately, cirrhosis and carcinoma, which...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382298/ https://www.ncbi.nlm.nih.gov/pubmed/30828530 http://dx.doi.org/10.1002/advs.201801585 |
_version_ | 1783396645686214656 |
---|---|
author | Yu, Yao Cai, Jingjing She, Zhigang Li, Hongliang |
author_facet | Yu, Yao Cai, Jingjing She, Zhigang Li, Hongliang |
author_sort | Yu, Yao |
collection | PubMed |
description | Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease which affects ≈25% of the adult population worldwide, placing a tremendous burden on human health. The disease spectrum ranges from simple steatosis to steatohepatitis, fibrosis, and ultimately, cirrhosis and carcinoma, which are becoming leading reasons for liver transplantation. NAFLD is a complex multifactorial disease involving myriad genetic, metabolic, and environmental factors; it is closely associated with insulin resistance, metabolic syndrome, obesity, diabetes, and many other diseases. Over the past few decades, countless studies focusing on the investigation of noninvasive diagnosis, pathogenesis, and therapeutics have revealed different aspects of the mechanism and progression of NAFLD. However, effective pharmaceuticals are still in development. Here, the current epidemiology, diagnosis, animal models, pathogenesis, and treatment strategies for NAFLD are comprehensively reviewed, emphasizing the outstanding breakthroughs in the above fields and promising medications in and beyond phase II. |
format | Online Article Text |
id | pubmed-6382298 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-63822982019-03-01 Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases Yu, Yao Cai, Jingjing She, Zhigang Li, Hongliang Adv Sci (Weinh) Reviews Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease which affects ≈25% of the adult population worldwide, placing a tremendous burden on human health. The disease spectrum ranges from simple steatosis to steatohepatitis, fibrosis, and ultimately, cirrhosis and carcinoma, which are becoming leading reasons for liver transplantation. NAFLD is a complex multifactorial disease involving myriad genetic, metabolic, and environmental factors; it is closely associated with insulin resistance, metabolic syndrome, obesity, diabetes, and many other diseases. Over the past few decades, countless studies focusing on the investigation of noninvasive diagnosis, pathogenesis, and therapeutics have revealed different aspects of the mechanism and progression of NAFLD. However, effective pharmaceuticals are still in development. Here, the current epidemiology, diagnosis, animal models, pathogenesis, and treatment strategies for NAFLD are comprehensively reviewed, emphasizing the outstanding breakthroughs in the above fields and promising medications in and beyond phase II. John Wiley and Sons Inc. 2018-12-12 /pmc/articles/PMC6382298/ /pubmed/30828530 http://dx.doi.org/10.1002/advs.201801585 Text en © 2018 The Authors. Published by WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Reviews Yu, Yao Cai, Jingjing She, Zhigang Li, Hongliang Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases |
title | Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases |
title_full | Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases |
title_fullStr | Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases |
title_full_unstemmed | Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases |
title_short | Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases |
title_sort | insights into the epidemiology, pathogenesis, and therapeutics of nonalcoholic fatty liver diseases |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382298/ https://www.ncbi.nlm.nih.gov/pubmed/30828530 http://dx.doi.org/10.1002/advs.201801585 |
work_keys_str_mv | AT yuyao insightsintotheepidemiologypathogenesisandtherapeuticsofnonalcoholicfattyliverdiseases AT caijingjing insightsintotheepidemiologypathogenesisandtherapeuticsofnonalcoholicfattyliverdiseases AT shezhigang insightsintotheepidemiologypathogenesisandtherapeuticsofnonalcoholicfattyliverdiseases AT lihongliang insightsintotheepidemiologypathogenesisandtherapeuticsofnonalcoholicfattyliverdiseases |